D. Boral Capital Cuts Immunic (NASDAQ:IMUX) Price Target to $4.00

Immunic (NASDAQ:IMUX) had its price target decreased by D. Boral Capital from $8.00 to $4.00 in a report issued on Friday,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

Several other equities analysts also recently issued reports on the stock. Roth Mkm initiated coverage on shares of Immunic in a research note on Friday, November 7th. They set a “buy” rating and a $3.00 price objective on the stock. Brookline Capital Acquisition raised shares of Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Chardan Capital raised Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Finally, Brookline Cap M upgraded Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunic currently has an average rating of “Buy” and an average price target of $6.60.

Immunic Stock Performance

NASDAQ:IMUX opened at $0.91 on Friday. Immunic has a 1 year low of $0.51 and a 1 year high of $1.39. The stock has a market cap of $109.76 million, a P/E ratio of -1.10 and a beta of 1.58. The stock has a 50-day simple moving average of $0.64 and a 200-day simple moving average of $0.76.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. On average, equities research analysts predict that Immunic will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently modified their holdings of the company. Aberdeen Group plc grew its holdings in Immunic by 678.1% in the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock worth $5,750,000 after buying an additional 7,184,457 shares in the last quarter. Nantahala Capital Management LLC acquired a new position in Immunic during the 4th quarter worth $2,337,000. Vanguard Group Inc. grew its stake in shares of Immunic by 5.3% in the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after purchasing an additional 219,957 shares in the last quarter. Focus Partners Wealth grew its stake in shares of Immunic by 1.5% in the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after purchasing an additional 39,063 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Immunic by 13.8% during the fourth quarter. Geode Capital Management LLC now owns 1,176,285 shares of the company’s stock valued at $628,000 after purchasing an additional 142,513 shares during the period. Institutional investors own 51.82% of the company’s stock.

Immunic News Roundup

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: Immunic priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds, with $200 million in upfront cash. Immunic Announces Oversubscribed Private Placement
• Positive Sentiment: The company says proceeds will fund completion of Phase 3 ENSURE trials in relapsing MS, start a Phase 3 in primary progressive MS, and finance the transition to a commercial organization — milestones that reduce near-term financing risk if achieved. Immunic shares gain on $400M raise to fund late-stage MS trials, commercial push
• Positive Sentiment: Board and leadership moves: Simona Skerjanec (ex‑Roche neuroscience head) was named interim Chairperson, Thor Nagel (BVF Partners) joined the board, and the company launched a search for a commercially experienced CEO — actions that signal preparation for commercialization. Immunic Announces Oversubscribed Private Placement
• Neutral Sentiment: An analyst note lowered Immunic’s price target (D. Boral Capital cut from $8 to $4) but maintained a buy rating — a reminder that sell‑side sentiment remains mixed and some upside expectations were trimmed. Analyst Price Target Cut
• Negative Sentiment: Significant dilution risk: the financing includes issuance of 229,076,000 pre‑funded warrants priced at $0.873 each for $200M upfront and accompanying warrants that could bring another $200M if exercised — a large potential increase in share count that could pressure the stock long term. Immunic to raise up to $400M to fund late-stage MS trials, commercial push

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.